BELLUS Health (BLU) Short Interest Ratio & Short Volume

Short interest is the volume of BELLUS Health shares that have been sold short but have not yet been closed out or covered. As of June 15th, traders have sold 6,650,000 shares of BLU short. Learn More on BELLUS Health's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BLU shares currently have a short interest ratio of 1.0. Learn More on BELLUS Health's short interest ratio.

BELLUS Health saw a decline in short interest in June. As of June 15th, there was short interest totaling 6,650,000 shares, a decline of 12.4% from the previous total of 7,590,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the sector of "medical" compare to BELLUS Health: Ginkgo Bioworks Holdings, Inc. (20.21%), Geron Co. (8.53%), NewAmsterdam Pharma (0.86%), Beam Therapeutics Inc. (16.34%), Twist Bioscience Co. (21.20%), Fusion Pharmaceuticals Inc. (6.13%), NeoGenomics, Inc. (5.67%), Recursion Pharmaceuticals, Inc. (27.13%), Galapagos NV (2.18%), Maravai LifeSciences Holdings, Inc. (4.79%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.80 billion), Canadian Natural Resources Limited ($3.69 billion), Charter Communications, Inc. ($2.95 billion), Occidental Petroleum Co. ($2.78 billion), Moderna, Inc. ($2.38 billion), Palantir Technologies Inc. ($2.29 billion), T. Rowe Price Group, Inc. ($2.19 billion), Coinbase Global, Inc. ($2.08 billion), Royal Caribbean Cruises Ltd. ($2.02 billion), and Verisk Analytics, Inc. ($1.96 billion). View all of the most shorted stocks.

Short selling BLU is an investing strategy that aims to generate trading profit from BELLUS Health as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for BELLUS Health occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BLU, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BLU, twice per month. The most recent reporting period available is June, 15 2023.